Business Context and Reporting Period
This Form 8-K Current Report was filed by Oracle Corporation on July 7, 2021, covering the date of the earliest event reported on June 30, 2021. The filing addresses corporate governance and management matters, specifically an amendment to executive compensation arrangements.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on a specific executive compensation amendment and does not contain financial performance data for the period.
Material Changes
The primary material change reported is the approval by the Compensation Committee of the Board of Directors on June 30, 2021, of an amendment to the Performance Stock Options (PSOs) granted on July 20, 2017, to Lawrence J. Ellison (Chairman, CTO, Founder) and Safra A. Catz (CEO, Director). Key details include:
- Term Extension: The performance period for the PSOs was extended by three additional fiscal years, from May 31, 2022, to May 31, 2025.
- Vesting Status: The stock price goal and the first market capitalization goal have been certified as achieved. Consequently, one tranche (representing one-seventh of the PSOs) has vested.
- Future Vesting: Additional tranches may vest if remaining operational and market capitalization performance goals are achieved before May 31, 2025.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on business outlook, or specific risk factors beyond the standard contingencies inherent in performance-based compensation. The vesting of future tranches is contingent upon achieving specific operational and market capitalization goals by the new deadline.
Investor Verification Checklist
- Verify the specific operational and market capitalization performance goals required for the remaining PSO tranches by reviewing the 2020 Proxy Statement.
- Review Exhibit 10.15 (First Amendment to Performance-Based Stock Option Agreement) for the full legal terms of the amendment.
- Confirm the impact of the extended performance period on future dilution and executive compensation expenses in upcoming quarterly reports.